The first approach for tau active immunization was to immunize normal C57BL6J mice with full-length recombinant human tau whose response included the display of encephalomyelitis, axonal damage, and inflammation (Rosenmann et al., 2006). The gene discussed is MAPT; the disease is encephalomyelitis.